Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions

Cancer Treatment Reviews

Volumn 40, Issue 3, 2014, Pages 390-404

  Schmitz, Sandra ^a   Ang, Kie Kian ^b   Vermorken, Jan ^c   Haddad, Robert ^d   Suarez, Carlos ^e   Wolf, Gregory T ^f   Hamoir, Marc ^a   Machiels, Jean Pascal ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Head neck cancer; Molecular biology; Squamous cell carcinoma; Targeted therapies; Treatment

Indexed keywords

ABT 806; AFATINIB; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; DACOMITINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FUTUXIMAB; GEFITINIB; HEAT SHOCK PROTEIN; HISTONE DEACETYLASE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; NIMOTUZUMAB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN KINASE B; SARACATINIB; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; STAT PROTEIN; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; ZALUTUMUMAB;

ANGIOGENESIS; CANCER RECURRENCE; CANCER THERAPY; ECONOMIC EVALUATION; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RECEPTOR BLOCKING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; WART VIRUS;

HEAD & NECK CANCER; MOLECULAR BIOLOGY; SQUAMOUS CELL CARCINOMA; TARGETED THERAPIES; TREATMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84892848118     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.09.007     Document Type: Review

References (187)

1. http://www.globoscan.iarc.fr.
2. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
3. Gillison M.L. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004, 31:744-754.
4. Grégoire V., Lefebvre J.-L., Licitra L., Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v184-v186.
5. Yotsumoto F., Yagi H., Suzuki S.O., et al. Validation of HB-EGF and amphiregulin as target for human cancer therapy. Biochem Biophys Res Commun 2008, 365:555-561.
6. Kalyankrishna S., Grandis J.R. Epidermal growth factor biology in head and neck cancer. J Clin Oncol 2006, 24:2666-2672.
7. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62:7350-7356.
8. Wheeler S., Siwak D.R., Chai R., et al. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 2012, 18:2278-2289.
9. Rubin Grandis J.R., Melhem M.F., Gooding W.E., et al. Levels of TGFA and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-832.
10. Jedlinski A., Ansell A., Johansson A.C., Roberg K.J. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines. Oral Pathol Med 2013, 42:26-36.
11. Bentzen S.M., Atasoy B.M., Daley F.M., et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005, 23:5560-5567.
12. Dittmann K., Mayer C., Fehrenbacher B., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005, 280:31182-31189.
13. Dittmann K., Mayer C., Ohneseit P.A., et al. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys 2008, 70:203-212.
14. Dittmann K., Mayer C., Rodemann H.P. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 2005, 76:157-161.
15. Walker F., Zhang H.H., Burgess A.W. Identification of a novel EGF-sensitive cell cycle checkpoint. Exp Cell Res 2007, 313:511-526.
16. Liccardi G., Hartley J.A., Hochhauser D. EGFR Nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 2011, 71:1103-1114.
17. Husain H., Psyrri A., Markovic A., et al. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope 2012, 122:2762-2768.
18. Psyrri A., Yu Z., Weinberger P.M., et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005, 11:5856-5862.
19. Temam S., Kawaguchi H., El-Naggar A.K., et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007, 25:2164-2170.
20. Mrhalova M., Plzak J., Betka J., Kodet R. Epidermal growth factor receptor-its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinoma. Neoplasma 2005, 52:338-343.
21. Chung C.H., Ely K., McGavran L., et al. Increased epidermal growth factor receptor gene copy number is associated with poor progonis in head and neck squamous cell carcinomas. J Clin Oncol 2006, 24:4170-4176.
22. Chiang W.F., Liu S.Y., Yen C.Y., et al. Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinoma. Oral Oncol 2008, 44:270-276.
23. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14:467-475.
24. Gillison M.L., D'Souza G., Westra W., et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008, 100:407-420.
25. Narisawa-Saito M., Kiyono T. Basic mechanisms of high risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci 2007, 98:1505-1511.
26. Slebos R.J., Yi Y., Ely K., et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006, 12:701-709.
27. Nichols A.C., Chan-Seng-Yue M., Yoo J., et al. A pilot study comparing HPV-positive and HPV-negative head and neck squamous cell carcinomas by whole exome sequencing. ISRN Oncol 2012, 2012:809370.
28. Weinberger P.M., Yu Z., Kountourakis P., et al. Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol Head Neck Surg 2009, 141:382-389.
29. Smith E.M., Rubenstein L.M., Hoffman H., Haugen T.H., Turek L.P. Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. Infect Agent Cancer 2010, 5:4.
30. Gillison M.L., Harris J., Westra W., et al. Radiation therapy oncology group. survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol 2009, 27:15s. (abstr 6003).
31. Morrow M.P., Yan J., Sardesai N.Y. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines 2013, 12:271-283.
32. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
33. Hama T., Yuza Y., Saito Y., et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 2009, 14:900-908.
34. Loeffler-Ragg J., Witsch-Baumgartner M., Tzankov A., Hilbe W., Schwentner I., Sprinzl G.M. Low incidence of mutations in EGFR kinase domain in caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006, 42:109-111.
35. Schwentner I., Witsch-Baumgartner M., Sprinzl G.M. Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. Head Neck 2008, 30:1040-1044.
36. Bigner S.H., Humphrey P.A., Wong A.J., et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990, 50:8017-8022.
37. Sok J.C., Coppelli F.M., Thomas S.M., et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006, 12:5064-5073.
38. Chau N.G., Perez-Ordonez B., Zhang K., et al. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol 2011, 3:11.
39. Moscatello D.K., Holgado-Madruga M., Emlet D.R., Montgomery R.B., Wong A.J. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998, 273:200-206.
40. Wheeler S.E., Suzuki S., Thomas S.M., et al. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene 2010, 29:5135-5145.
41. Tinhofer I., Klinghammer K., Weichert W., et al. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2011, 17:5197-5204.
42. Agrawal N., Frederick M.J., Pickering C.R., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
43. Leemans C.R., Braakhuis B.J., Braakenhoff R.H. The molecular biology of head and neck cancer. Nat Rev Cancer 2011, 11:9-22.
44. Stransky N., Egloff A.M., Tward A.D., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
45. Gillison M.L. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004, 31:744-754.
46. Li S., Schmitz K.R., Jeffrey P.D., et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
47. Lopez-Albaitero A., Lee S.C., Morgan S., et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009, 58:1853-1864.
48. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59:1935-1940.
49. Chen D.J., Nirodi C.S. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007, 13:6555-6560.
50. Milas L., Mason K., Hunter N. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000, 6:701-708.
51. Bonner J.A., Harari P.M., Girald J., et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
52. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-28.
53. Pignon J.P., Bourhis J., Domenge C., Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000, 355:949-955.
54. Ang K.K., Zhang Q., Rosenthal D.I., et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011, 29:15s. (abst 5500).
55. Lefebvre J.L., Pointreau Y., Rolland F., et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013, 31:853-859.
56. Ghi M.G., Paccagnella A., Ferrari D., et al. A phase II-III study comparing concomitant chemoradiotherapy (CRT) versus cetuximab/RT (CET/RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): efficacy results (NCT01086826). J Clin Oncol 2013, 31. (suppl; abstr 6003).
57. Baselga J., Trigo J.M., Bourhis J., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005, 23:5568-5577.
58. Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005, 23:5578-5587.
59. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007, 25:2171-2177.
60. Vermorken J.B., Herbst R.S., Leon X., Amellal N., Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008, 112:2710-2719.
61. León X., Hitt R., Constenla M., et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol 2005, 17:418-424.
62. http://www.fda.gov.
63. Burtness B., Goldwasser M.A., Flood W., Mattar B., Mattar A.A. Eastern cooperative oncology groupe. Phase IIIrandomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern cooperative oncology group study. J Clin Oncol 2005, 23:8646-8654.
64. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
65. Psyrri A., Licitra L., DeBlas B., Celik I., Vermorken J.B. Safety and efficacy of cisplatin plus 5-FU and cetuximab in HPV-positive and HPV-negative recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the phase III EXTREME trial. Ann Oncol 2012, 23(Suppl. 9):ix334-ix347.
66. Machiels J.P., Subramanian S., Ruzsa A., et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011, 12:333-343.
67. Vermorken J.B., Stöhlmacher-Williams J., Davidenko I., et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013, 14:697-710.
68. Stoehlmacher-Williams J., Villanueva C., Foa P., et al. Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the global phase III SPECTRUM trial. J Clin Oncol 2012, 20:15s. (abstr 5504).
69. Giralt J., Fortin A., Mesia R., et al. A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 2012, 30:15. (abstr 2000).
70. Giralt J., Trigo J.M., Nuyts S., et al. Phase 2, randomized trial (Concert-2) of panitumumab (Pmab) plus radiotherapy (PRT) compared with chemotherapy (CRT) in patients (pts) with unresected locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Abstract 10160. Ann Oncol 2012, 23(Suppl. 9):ix334-ix347.
71. Wirth L.J., Dakhil S.R., Kornek G., et al. PARTNER: A randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol 2013, 31. (abstr 6029).
72. Rodríguez M.O., Rivero T.C., Del Castillo Bahi R. et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010, 9:343-349.
73. Babu K.G., Viswanath L., Reddy B.K., et al. An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four-year survival results from a phase IIb study. J Clin Oncol 2010, 28:15. (abst 5530).
74. Cleary J.M., Yee K.-C.L., Azad N., et al. A phase 1 study of ABT-806, a 40humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors. Cancer Res 2012, 72:s1. (Abstract 2506).
75. Gan H.K., Burge M.E., Solomon B.J., et al. A phase I and biodistribution study of ABT-806i, an [111] indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806. J Clin Oncol 2013, 31:15S. (abst 2520).
76. Lai S.Y., Koppikar P., Thomas S.M., et al. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 2009, 10(27):1235-1242.
77. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004, 22:77-85.
78. Cohen E.E., Rosen F., Stadler W.M., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003, 15(21):1980-1987.
79. Stewart J.S., Cohen E.E., Licitra L., et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009, 27:1864-1871.
80. Argiris A., Ghebremichael M., Gilbert J., Burtness B., Forastiere A. A phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013 Apr 10, 31(11):1405-1414.
81. Martins R.G., Parvathaneni U., Bauman J.E., et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol 2013, 31:1415-1421.
82. Gregoire V., Hamoir M., Chen C., et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiother Oncol 2011, 100:62-69.
83. Harrington K., Berrier A., Robinson M., et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer 2012, 19:9.
84. Del Campo J.M., Hitt R., Sebastian P., et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011, 105:618-627.
85. De Souza J.A., Davis D.W., Zhang Y., et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2012, 18:2336-2343.
86. Lalami Y., Specenier P.M., Awada A., et al. EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. Radiother Oncol 2012, 105(2):238-240.
87. Seiwert T.Y., Fayette J., Cupissol D., et al. A randomized, open-label, phase II study of Afatinib versus Cetuximab in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2012, 23:xi35-xi36.
88. Cupissol D., Seiwert T.Y., Fayette J., et al. A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of stage 2 (S2) following crossover. J Clin Oncol 2013, 31. (abstr 6001).
89. Abdul Razak A.R., Soulières D., Laurie S.A., et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 2013, 24:761-769.
90. Yonesaka K., Zejnullahu K., Okamoto I., et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011, 3. [99ra86].
91. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9(7):463-475.
92. Wilson T.R., Lee D.Y., Berry L., Shames D.S., Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011, 20:158-172.
93. Schaefer G., Haber L., Crocker L.M., et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20:472-486.
94. Cervantes-Ruiperez A., Juric D., Hidalgo M., et al. A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: expansion cohorts. J Clin Oncol 2009, 27:15s. (abstr 2565).
95. Schroeder P., Lindemann C., Dettmar K., et al. Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell. Clin Transl Oncol 2011, 13:889-898.
96. Pedersen M.W., Jacobsen H.J., Koefoed K., et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010, 70:588-597.
97. Machiels J.P., Specenier P.M., Krauss J., et al. Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after monoclonal antibody: a proof of concept study. J Clin Oncol 2013, 31. (abstr 6002).
98. Trusolino L., Bertotti A., Comoglio P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010, 11:834-848.
99. Engelman J.A., Zejnullahu K., Gale C.M., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67:11924-11932.
100. Turke A.B., Zejnullahu K., Wu Y.L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
101. Benedettini E., Sholl L.M., Peyton M., et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 2010, 177:415-423.
102. Agarwal S., Zerillo C., Kolmakova J., et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 2009, 100:941-949.
103. Seiwert T.Y., Jagadeeswaran R., Faoro L., et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009, 69:3021-3031.
104. Kim C.H., Koh Y.W., Han J.H. C-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck 2010, 32:1655-1664.
105. Ghadjar P., Blank-Liss W., Simcock M. MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clin Exp Metastasis 2009, 26:809-815.
106. Xu H., Stabile L.P., Gubish C.T., et al. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 2011, 17:4425-4438.
107. Knowles L.M., Stabile L.P., Egloff A.M., et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009, 15:3740-3750.
108. Seiwert T., Sarantopoulos J., Kallender H., McCallum S., Keer H.N., Blumenschein G. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2012, 31:417-424.
109. Yap T.A., Olmos D., Brunetto A.T., et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011, 29:1271-1279.
110. Kurihara S., Hakuno F., Takahashi S. Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: the roles of MAP kinase pathway and PI 3-kinase pathway. Endocr J 2000, 47:739-751.
111. Tang Y., Zhang D., Fallavollita L., Brodt P. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res 2003, 63:1166-1171.
112. Resnicoff M., Abraham D., Yutanawiboonchai W., Rotman H.L., et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995, 55:2463-2469.
113. Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 2005, 9:753-768.
114. Barnes C.J., Ohshiro K., Rayala S.K., El-Naggar A.K., Kumar R. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007, 13:4291-4299.
115. Jun H., Chang M., Ko Y., et al. Clinical significance of type 1 insulin-like growth factor receptor and insulin-like growth factor binding protein-3 expression in squamous cell carcinoma of head and neck. J Clin Oncol 2009, 27:15s. (abstr 6036).
116. Schmitz S., Kaminsky-Forrett M.C., Henry S., et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 2012, 23:2153-2161.
117. Glisson B.S., Tseng J., Marur S., et al. Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN). J Clin Oncol 2013, 31. (abstr 6030).
118. Calvani M., Rapsiarda A., Uranchimeg B., Shoemaker R.H., Melillo G. Hypoxic induction of an HIF-1a-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 2006, 107:2705-2712.
119. Lewis C.E., Hughes R. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res 2007, 9:209.
120. Jiang Y., Dai A., Li Q., Hu R. Hypoxia induces transforming growth factor b1 gene expression in the pulmonary artery of rats with hypoxia-inductible factor-1a. Acta Biochim Biophys Sin 2007, 39:73-80.
121. Kyzas P.A., Cunha I.W., Ioannidis J.P. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005, 11:1434-1440.
122. Hirakawa S., Brown L.F., Kodama S., Paavonen K., Alitalo K., Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007, 109(3):1010-1017.
123. Kudo Y., Iizuka S., Yoshida M., et al. Periostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer. PLOS One 2012, 7:e44488.
124. Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodeling is defined by pericyte coverage of the performed endothelial network and is regulated by BDGF-B and VEGF. Development 1998, 125:1591-1598.
125. Erber R., Thurnher A., Katsen A., et al. Combined inhibition of VEGF-and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18:338-340.
126. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeted both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295.
127. Argiris A., Karamouzis M.V., Gooding W.E., et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011, 29:1140-1145.
128. Cohen E., Davis D., Karrison T., et al. A phase II study of erlotinib and bevacizumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Lancet Oncol 2009, 10:247-257.
129. Seiwert T.Y., Haraf D.J., Cohen E.E., et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008, 26:1732-1741.
130. Salama J.K., Haraf D.J., Stenson K.M., et al. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol 2011, 22:2304-2309.
131. Harari P.M., Khuntia D., Traynor A.M., et al. Phase I trial of bevacizumab combined with concurrent chemoradiation for squamous cell carcinoma of the head and neck: preliminary outcome results. J Clin Oncol 2011, 29:15s. (abstract 5518).
132. Fury M.G., Lee N.Y., Sherman E., et al. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer 2012, 118:5008-5014.
133. Argiris A., Kotsakis A.P., Hoang T., et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2013, 24:220-225.
134. Saura C., Baselga J., Herbst R., et al. Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): an open-label exploratory study. J Clin Oncol 2009, 27:15S. (abst 6023).
135. Machiels J.P., Henry S., Zanetta S., et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010, 28:21-28.
136. Fountzilas G., Fragkoulidi A., Kalogera-Fountzila A., et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 2010, 65:649-660.
137. Choong N.W., Kozloff M., Taber D., et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2010, 28:677-683.
138. Williamson S.K., Moon J., Huang C.H., et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: southwest oncology group study S0420. J Clin Oncol 2010, 28:3330-3335.
139. Blumenschein G.R., Glisson B.S., Lu C., et al. Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). Journal of Clinical Oncology 2012, 30:15S. (abst 5592).
140. Sano D., Matsumoto F., Valdecanas D.R., et al. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 2011, 17:1815-1827.
141. Sano D., Kawakami M., Fujita K., et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 2007, 17:289-295.
142. Molinolo A.A., Hewitt S.M., Amornphimoltham P., et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007, 13:4964-4973.
143. Gupta A.K., McKenna W.G., Weber C.N., et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002, 8:885-892.
144. Janku F., Tsimberidou A.M., Garrido-Laguna I., et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011, 10:558-565.
145. Garrido-Laguna I., Janku F., Tsimberidou A. Et al Phosphatase and tensin homologue (PTEN) loss and response to phase I trials targeting PI3K/AKT/mTOR pathway in patients with advanced cancer. J Clin Oncol 2010, 28:15S. (e13018).
146. Argiris A., Cohen E., Karrison T., et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006, 5:766-770.
147. Cassell A., Freilino M.L., Lee J., et al. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia 2012, 14:1005-1014.
148. Bozec A., Etienne-Grimaldi M.C., Fischel J.L., et al. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral Oncol 2011, 47:340-344.
149. Aissat N., Le Tourneau C., Ghoul A., et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008, 62(2):305-313.
150. Bauman J.E., Arias-Pulido H., Lee S.-J., et al. Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2012, 30:15s. (abstr 5549).
151. Raymond E., LeTourneau C., Gatineau M., et al. CAPRA: Safety, efficacy, and translational biomarkers of weekly everolimus, carboplatin, and paclitaxel as induction therapy for locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2013, 31. (abstr 6036).
152. Bonner J.A., Yang E.S., Trummell H.Q., et al. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother Oncol 2011, 99:339-343.
153. Sen M., Joyce S., Panahandeh M., et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 2012, 18:4986-4996.
154. Raju U., Riesterer O., Wang Z.Q., et al. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol 2012, 105:241-249.
155. Brooks H.D., Glisson B.S., Bekele B.N., et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 2011, 117:2112-2119.
156. Fury M.G., Baxi S., Shen R., et al. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res 2011, 31:249-253.
157. Lin Y.C., Wu M.H., Wei T.T., et al. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells. Neoplasia 2012, 14:463-475.
158. Adams J., Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest 2004, 22:304-311.
159. Sunwoo J.B., Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7:1419-1428.
160. Chung C.H., Aulino J., Muldowney N.J., et al. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2010, 21:864-870.
161. Argiris A., Duffy A.G., Kummar S., et al. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res 2011, 17:5755-5764.
162. Gilbert J., Lee J.W., Argiris A., et al. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the eastern cooperative oncology group. Head Neck 2012, 13.
163. Jung M., Zhang Y., Dimtchev A., Dritschilo A. Impaired regulation of nuclear factor-kappaB results in apoptosis induced by gamma radiation. Radiat Res 1998, 149:596-601.
164. Rikiishi H., Shinohara F., Sato T., Sato Y., Suzuki M., Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 2007, 30:1181-1188.
165. Haigentz M., Kim M., Sarta C., et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 2012, 48:1281-1288.
166. Okui T., Shimo T., Hassan N.M., et al. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma. Anticancer Res 2011, 31:1197-1204.
167. Zaidi S., McLaughlin M., Bhide S.A., et al. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One 2012, 7:e35436.
168. Ahsan A., Ramanand S.G., Whitehead C., et al. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia 2012, 14:670-677.
169. Borggrefe T., Liefke R. Fine-tuning of the intracellular canonical notch signaling pathway. Cell Cycle 2012, 11(2):264-276.
170. Lin J.T., Chen M.K., Yeh K.T., et al. Association of high levels of jagged-1 and notch-1 expression with poor prognosis in head and neck cancer. Ann Surg Oncol 2010, 17:2976-2983.
171. Gu F., Ma Y., Zhang Z., et al. Expression of stat3 and notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 2010, 23:671-676.
172. Hijioka H., Setoguchi T., Miyawaki A., et al. Upregulation of notch pathway molecules in oral squamous cell carcinoma. Int J Oncol 2010, 36:817-822.
173. Machiels J.P., Schmitz S. The importance of window opportunity studies. Ann Oncol 2012, 23(Suppl. 9):ix42-ix43.
174. Primdahl H., Nielsen A.L., Larsen S., et al. Changes from 1992 to 2002 in the pretreatment delay for patients with squamous cell carcinoma of larynx or pharynx: a Danish nationwide survey from DAHANCA. Acta Oncol 2006, 45:156-161.
175. Allison P., Franco E., Black M., Feine J. The role of professional diagnostic delays in the prognosis of upper aerodigestive tract carcinoma. Oral Oncol 1998, 34:147-153.
176. Jensen A.R., Nellemann H.M., Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol 2007, 84:5-10.
177. Thomas F., Rochaix P., Benlyazid A., et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 2007, 13:7086-7092.
178. Thomas F., Delmar P., Vergez S., et al. Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma. Head Neck 2013, 35:809-818.
179. Schmitz S., Hamoir M., Reychler H., et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann Oncol 2013, 24(9):2261-2266.
180. Ferris, R. Surgical immunotherapy. Ferris RL, oral communication at ASCO meeting 2012, Chicago.
181. Keogh B. Era of personalized medicine may herald end of soaring cancer costs. J Natl Cancer Inst 2012, 104:12-17.
182. McCabe C., Bergmann L., Bosanquet N., et al. Biotherapy development association. market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol 2009, 20:403-412.
183. Atherly A.J., Camidge D.R. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer 2012, 106:1100-1106.
184. Trowman R., Chung H., Longson C., Littlejohns P., Clark P. The national institute for health and clinical excellence and its role in assessing the value of new cancer treatments in England and Wales. Clin Cancer Res 2011, 17:4930-4935.
185. Shih Y.-C.T., Halpern M.T. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?. CA Cancer J Clin 2008, 58:231-244.
186. Valachis A., Polyzos N.P., Nearchou A., Lind P., Mauri D. Financial relationships in economic analyses of targeted therapies in oncology. J Clin Oncol 2012, 30:1316-1320.
187. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.K. Cancer genome landscapes. Science 2013, 339:1546-1558.